NYSE · ANRO
Healthcare · Biotechnology
$24.01
Down-$0.32 (-1.33%)
Updated Oct 7, 2026, 1:03 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ANRO
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ANRO closed at $24.01 after 20 trading sessions, down 32.95% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $24.63 | $25.85 | $23.795 | $24.01 | 550.29K |
| Oct 2, 2026 | $25.64 | $26.10 | $23.87 | $24.80 | 660.69K |
| Oct 1, 2026 | $25.50 | $26.49 | $25.12 | $25.31 | 575.79K |
| Sep 30, 2026 | $26.87 | $27.41 | $25.53 | $25.53 | 891.62K |
| Sep 29, 2026 | $26.44 | $27.42 | $25.745 | $26.58 | 763.38K |
| Sep 28, 2026 | $26.36 | $27.76 | $25.89 | $26.66 | 587K |
| Sep 25, 2026 | $27.36 | $27.615 | $26.48 | $26.49 | 366.27K |
| Sep 24, 2026 | $27.51 | $27.91 | $26.385 | $27.18 | 788.43K |
| Sep 23, 2026 | $30.39 | $30.6149 | $26.41 | $27.50 | 639.85K |
| Sep 22, 2026 | $30.71 | $31.46 | $30.175 | $30.78 | 347.07K |
| Sep 21, 2026 | $30.64 | $30.81 | $29.80 | $30.63 | 357.8K |
| Sep 18, 2026 | $31.32 | $31.65 | $30.08 | $30.27 | 2.2M |
| Sep 17, 2026 | $30.59 | $31.65 | $30.11 | $30.98 | 410.96K |
| Sep 16, 2026 | $30.50 | $31.21 | $29.8673 | $30.00 | 548.38K |
| Sep 15, 2026 | $31.40 | $31.40 | $29.945 | $30.25 | 420.36K |
| Sep 14, 2026 | $31.96 | $32.985 | $31.16 | $31.68 | 453.31K |
| Sep 11, 2026 | $32.00 | $33.1327 | $31.11 | $32.00 | 415.74K |
| Sep 10, 2026 | $33.71 | $34.20 | $31.35 | $31.68 | 790.03K |
| Sep 9, 2026 | $35.48 | $36.91 | $33.9067 | $34.07 | 556.88K |
| Sep 8, 2026 | $34.69 | $36.84 | $34.08 | $35.81 | 580.96K |
The latest Smart Investors Daily articles mentioning ANRO.
Company
Market Activity
Research & News
ANRO research
Company profile and research snapshot.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | Wedbush | Neutral | — |
| Aug 13, 2026 | BTIG | Buy | — |
| May 18, 2026 | Baird | Outperform | — |
| May 14, 2026 | Wedbush | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
MOUNTAIN VIEW, Calif., September 09, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:
Yahoo · Aug 27, 2026
MOUNTAIN VIEW, Calif., August 27, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026.
Benzinga · Aug 27, 2026
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief
Benzinga · Aug 17, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the price target from $50 to $55.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANRO.
